Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc.
Your view on GLUE
Overview
What the company does, where it operates, and who runs it.
About Monte Rosa Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Markus Warmuth
- Headquarters
- 645 Summer Street, Boston, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Markus Warmuth
- Headquarters
- 645 Summer Street, Boston, MA, US
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers.
The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies.
Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Monte Rosa Therapeutics, Inc., and the rating behind it. GLUE last traded at $14.07; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Monte Rosa Therapeutics, Inc.. Starting points for Monte Rosa Therapeutics, Inc.: EPS -$1.89, beta 1.50 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Monte Rosa Therapeutics, Inc.. Monte Rosa Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Monte Rosa Therapeutics, Inc.. Trailing twelve-month EPS for Monte Rosa Therapeutics, Inc. stands at -$1.89. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Monte Rosa Therapeutics, Inc.. Monte Rosa Therapeutics, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Monte Rosa Therapeutics, Inc. valued side by side against its closest peers. Monte Rosa Therapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Monte Rosa Therapeutics, Inc., and how their positions are changing. At a $1.19B market value, institutional positions materially move Monte Rosa Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Monte Rosa Therapeutics, Inc. executives and directors. Shares of Monte Rosa Therapeutics, Inc. have traded between $3.50 and $14.62 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Monte Rosa Therapeutics, Inc.. Monte Rosa Therapeutics, Inc. is a $1.19B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Monte Rosa Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Monte Rosa Therapeutics, Inc.. Coverage tracks Monte Rosa Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.